Quick Answer
InflaRx N.V. reported R&D Expense of $25.72 million for fiscal year 2025.
InflaRx N.V. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.72M | -27.3% |
| 2024 | $35.36M | -13.8% |
| 2023 | $41.02M | +9.3% |
| 2022 | $37.53M | +5.1% |
| 2021 | $35.70M | +39.0% |
| 2020 | $25.68M | -42.4% |
| 2019 | $44.58M | +78.1% |
| 2018 | $25.03M | +73.6% |
| 2017 | $14.41M | +173.1% |
| 2016 | $5.28M | +51.8% |
| 2015 | $3.48M | — |
- InflaRx N.V. showed a decrease of -27.3% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, InflaRx N.V.’s r&d expense has grown by 639.5% (from $3.48 million to $25.72 million).
- The most recent figure is from InflaRx N.V.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: